hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06378060, orgStudyIdInfo id: KM04, briefTitle: Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Hematology department of the 920th hospital, class: OTHER, descriptionModule briefSummary: The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia., conditionsModule conditions: Severe Aplastic Anemia, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Modified transplantation system, outcomesModule primaryOutcomes measure: overall survival (OS), primaryOutcomes measure: Acute graft-versus-host disease incidence, secondaryOutcomes measure: Transplantation-related motality, secondaryOutcomes measure: Chronic graft-versus-host disease incidence, secondaryOutcomes measure: incidence of Intensive fungal disease, secondaryOutcomes measure: EB virus reactivation rate, secondaryOutcomes measure: CMV reactivation rate, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 65 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, status: RECRUITING, city: Kunming, state: Yunnan, zip: 650000, country: China, contacts name: Wang PI sanbin, Doctor, role: CONTACT, phone: 0871-64774206, email: Wangsanbin2022@126.com, geoPoint lat: 25.03889, lon: 102.71833, hasResults: False
protocolSection identificationModule nctId: NCT06378034, orgStudyIdInfo id: 2023-A01926-39, briefTitle: Effect of Lactium on Sleep Disorders in Healthy Volunteers With Persistent Subclinical Insomnia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-10, primaryCompletionDateStruct date: 2024-07-15, completionDateStruct date: 2026-09-30, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Ingredia S.A., class: INDUSTRY, descriptionModule briefSummary: The main objective will be to assess the effect of Lactium® on sleep efficiency in volunteers presented with persistent subclinical insomnia., conditionsModule conditions: Sleep Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Lactium, interventions name: Placebo, outcomesModule primaryOutcomes measure: Sleep efficiency, secondaryOutcomes measure: Sleep diary, secondaryOutcomes measure: Insomnia Severity Index, secondaryOutcomes measure: PSQI, secondaryOutcomes measure: Sleep quality by cctigraphy, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 55 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06378021, orgStudyIdInfo id: Calcium chloride in CABG, briefTitle: Role of Calcium Chloride Injection in Alleviating Atrial Fibrillation Post CABG, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Helwan University, class: OTHER, descriptionModule briefSummary: This study hypothesize that injecting calcium chloride (CaCl2) into the major atrial ganglionated plexus (GPs) during on pump Coronary artery bypass graft (CABG) can reduce the incidence of Post operative Atrial fibrillation in the first 7 days after surgery.The study is designed to be prospective interventional study two armed RCT for on pump CABG patient.The intervention arm will be injected with Calcium chloride in the four major atrial ganglionic plexus The control arm will be injected with sodium chloride to determine the effect of Calcium chloride on Post CABG Atrial fibrillation, conditionsModule conditions: Atrial Fibrillation, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Calcium Chloride, interventions name: Sodium Chloride 0.9% Inj, outcomesModule primaryOutcomes measure: Change in number of patients who developed Atrial fibrillation, secondaryOutcomes measure: Change in length of hospital stay, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 74 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ain shams university, status: RECRUITING, city: Cairo, state: Abassia Cairo, zip: 02, country: Egypt, contacts name: Mohamed A Gamal, Ass prof, role: CONTACT, phone: 010080827060, phoneExt: 02, contacts name: Abdelhameed I Ebid, Prof, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06378008, orgStudyIdInfo id: 300100, briefTitle: A Clinical Study to Evaluate the Anti-Sensitivity Effect of a Calcium Sodium Phosphosilicate Toothpaste in a Population of Dentin Hypersensitivity Sufferers, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-16, primaryCompletionDateStruct date: 2024-09-13, completionDateStruct date: 2024-09-13, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: HALEON, class: INDUSTRY, descriptionModule briefSummary: The aim of this study is to confirm the clinical dentin hypersensitivity (DH) efficacy of a 5 percent (%) calcium sodium phosphosilicate (CSPS) toothpaste., conditionsModule conditions: Dentin Sensitivity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 234, type: ESTIMATED, armsInterventionsModule interventions name: CSPS toothpaste, interventions name: Regular fluoride toothpaste (Crest Cavity Protection), outcomesModule primaryOutcomes measure: Change from Baseline in Schiff Sensitivity Score at Day 56, secondaryOutcomes measure: Change from Baseline in Tactile Threshold at Day 56, secondaryOutcomes measure: Change from Baseline in Schiff Sensitivity Score at Days 3, 7, 14 and 28, secondaryOutcomes measure: Change from Baseline in Tactile Threshold at Days 3, 7, 14 and 28, secondaryOutcomes measure: Change from Baseline in Impact on Everyday Life (Section 1 of Dentin Hypersensitivity Experience Questionnaire [DHEQ-48], Question [Q]7-9) at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Total Score (Section 2, Question Q1-34) at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Restrictions Domain (Section 2, Q1-4) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Adaptation Domain Score (Section 2, Q5-16) at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Social Impact Domain (Section 2, Q17-21) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Emotional Impact Domain (Section 2, Q22-29) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Identity Domain (Section 2, Q30-34) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in Global Oral Health (Section 2, Q35) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in Effect on Life Overall (Section 2, Q36-39) Score at Days 28 and 56, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: All Sum Research, status: RECRUITING, city: Mississauga, state: Ontario, zip: L5N 6J2, country: Canada, contacts name: C R Goyal, Dr, role: CONTACT, geoPoint lat: 43.5789, lon: -79.6583, hasResults: False
protocolSection identificationModule nctId: NCT06377995, orgStudyIdInfo id: OST1_013, briefTitle: Effectiveness of an Intervention Plan Aimed at the Diaphragm in Chronic Non-specific Neck Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Escola Superior de Tecnologia da Saúde do Porto, class: OTHER, descriptionModule briefSummary: The aim of this study is to analyse the effectiveness of an intervention plan targeting the diaphragm, namely stretching technique, neuromuscular diaphragm and phrenic centre inhibition, in the treatment of chronic non-specific neck pain., conditionsModule conditions: Chronic Neck Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Double, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Placebo technique, interventions name: Diaphragm protocol, outcomesModule primaryOutcomes measure: Change in the intensity of pain in the cervical spine after applying the diaphragm intervention plan, primaryOutcomes measure: Changes in range of motion after applying the diaphragm targeted protocol, secondaryOutcomes measure: Changes in pain level one week after the intervention, secondaryOutcomes measure: Changes in range of motion one week later, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Escola Superior de Saúde do Porto, city: Porto, zip: 4200-072, country: Portugal, contacts name: Natália MO Campelo, PhD, role: CONTACT, phone: +35122 206 1000, email: nmc.ess.ipp@gmail.com, contacts name: Natália MO Campelo, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.14961, lon: -8.61099, hasResults: False
protocolSection identificationModule nctId: NCT06377982, orgStudyIdInfo id: SCCP001, briefTitle: Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2026-09, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: StemCyte Taiwan Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy, conditionsModule conditions: Cerebral Palsy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: hUCB, outcomesModule primaryOutcomes measure: safety-TEAE, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06377969, orgStudyIdInfo id: 75269, briefTitle: Prospective Evaluation of Effectiveness and Safety of Closed-Loop Spinal Cord Stimulation in Treating Patients With Chronic Pelvic Pain, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-06-30, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: Spinal cord stimulation (SCS) is an effective treatment for patients with chronic pelvic pain. The investigators will evaluate how safe and effective closed-loop spinal cord stimulation is in treating these patients; closed-loop spinal cord stimulation is a more novel method in delivering spinal cord stimulation that controls energy output of the device based on real-time feedback on how the device is stimulating the spinal cord., conditionsModule conditions: Chronic Pelvic Pain Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Pilot prospective single arm interventional study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: ECAP (Evoked Compound Action Potential)-controlled Closed-Loop Spinal Cord Stimulation, outcomesModule primaryOutcomes measure: Change in Pain Intensity, secondaryOutcomes measure: Change in Disability, secondaryOutcomes measure: Patient Global Impression Change, secondaryOutcomes measure: Change in Quality of Life, secondaryOutcomes measure: Change in Pain Catastrophizing Scale, secondaryOutcomes measure: Change in sleep quality, secondaryOutcomes measure: Change in Social Functioning, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06377956, orgStudyIdInfo id: XRGao, briefTitle: The Associations Between Gut Length, Gut Microbiota and Food Assimilation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, class: OTHER, descriptionModule briefSummary: The purpose of this observational study is to explore the correlation between human gut length and food absorption rates. This will include characterization of gut length, total food intake energy, fecal calories, urinary calories, body composition, food intake behavior, genetics and gut microbiota in the small intestine. Researchers expect to recruit up to 100 healthy volunteers., conditionsModule conditions: Gut Length, conditions: Food Assimilation Efficiency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Observation without intervention, outcomesModule primaryOutcomes measure: Gut length, primaryOutcomes measure: Energy intake, primaryOutcomes measure: Fecal calorie, primaryOutcomes measure: Urine calorie, primaryOutcomes measure: Weight, primaryOutcomes measure: Height, primaryOutcomes measure: Waist circumferences, primaryOutcomes measure: Hip circumferences, primaryOutcomes measure: Bone mass, primaryOutcomes measure: Fat mass, primaryOutcomes measure: Fat free mass, primaryOutcomes measure: Blood pressure, primaryOutcomes measure: Heart rate, primaryOutcomes measure: Resting energy expenditure, primaryOutcomes measure: Thermic effect of food, primaryOutcomes measure: Body shape, primaryOutcomes measure: Microbiome, primaryOutcomes measure: Metabolites, primaryOutcomes measure: Gut transit time, primaryOutcomes measure: Food macronutrient content, primaryOutcomes measure: Feces macronutrient content, primaryOutcomes measure: Total daily water volume, primaryOutcomes measure: Total daily urine volume, primaryOutcomes measure: Physical activity, primaryOutcomes measure: Bristol Stool Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shenzhen Institute of Advanced Technology, city: Shenzhen, state: Guangdong, zip: 518055, country: China, contacts name: John R Speakman, PhD, role: CONTACT, phone: 13466654659, email: j.speakman@abdn.ac.uk, geoPoint lat: 22.54554, lon: 114.0683, hasResults: False
protocolSection identificationModule nctId: NCT06377943, orgStudyIdInfo id: SIAT-IRB-240415-H0718, briefTitle: The Interaction Between Resting Metabolic Rate, Physical Activity and Thyroid Hormone in Females, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, class: OTHER, descriptionModule briefSummary: This Study is focused on the interaction between resting metabolic rate (RMR), physical activity (PA), and thyroid hormones (TH). TH controls almost all the cell activities of the body so, it is known as one of the major regulatory hormones. This is the reason for individuals who suffer from thyroid disorders show abnormal metabolism. Recently it was suggested that interindividual variations in thyroid hormone levels also influence daily physical activity., conditionsModule conditions: Thyroid, conditions: Physical Activities, conditions: Resting Energy Expenditure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, outcomesModule primaryOutcomes measure: Body weight, primaryOutcomes measure: Height, primaryOutcomes measure: Waist and Hip circumferences, primaryOutcomes measure: Fat mass, primaryOutcomes measure: Far free mass, primaryOutcomes measure: Bone mass, primaryOutcomes measure: Resting Metabolism, primaryOutcomes measure: Physical activity, primaryOutcomes measure: Thyroid hormone, secondaryOutcomes measure: Total energy expenditure, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06377930, orgStudyIdInfo id: RAP-219-FOS-201, briefTitle: Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Rapport Therapeutics Inc., class: INDUSTRY, descriptionModule briefSummary: This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy., conditionsModule conditions: Focal Onset Seizures, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: RAP-219, outcomesModule primaryOutcomes measure: Efficacy in reducing frequency of RNS-recorded long episodes in participants with FOS, secondaryOutcomes measure: Measurement of estimated electrographic seizure frequency from available RNS-recorded episodes, secondaryOutcomes measure: Measurement of Clinical Seizure Frequency, secondaryOutcomes measure: Change in seizure severity, secondaryOutcomes measure: Global Impression of Change, secondaryOutcomes measure: Pharmacokinetic parameters, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06377917, orgStudyIdInfo id: 2304-BRG-057-JF, briefTitle: Investigating Micro-Manipulation Procedures for Assisted Hatching Timing, acronym: IMPACT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Reproductive Medicine Associates of New Jersey, class: OTHER, descriptionModule briefSummary: This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility., conditionsModule conditions: Infertility, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Laser Assisted Hatching, outcomesModule primaryOutcomes measure: Blastulation Rate, secondaryOutcomes measure: Embryo morphologic grade, secondaryOutcomes measure: Timing of blastulation, secondaryOutcomes measure: Aneuploidy rate, secondaryOutcomes measure: Positive pregnancy rate, secondaryOutcomes measure: Sustained implantation rate, secondaryOutcomes measure: Pregnancy loss rate, secondaryOutcomes measure: Live birth rate, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 42 Years, stdAges: ADULT, contactsLocationsModule locations facility: Reproductive Medicine Associates of New Jersey, city: Marlton, state: New Jersey, zip: 08053, country: United States, contacts name: Christine V Whitehead, MS, BSN, RN, role: CONTACT, phone: 973-656-2841, email: clinicalresearchteam@ivirma.com, contacts name: Caroline Zuckerman, BS, RN, role: CONTACT, phone: 19736562841, email: clinicalresearchteam@ivirma.com, contacts name: Jason Fransiak, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Kevin Lambrese, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.89122, lon: -74.92183, hasResults: False